1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 75
Sponsor:
Protocol IDs: CNR-9505, EU-95023
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 25 to 65
Sponsor:
Protocol IDs: DFCI-75116
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 60
Sponsor:
Protocol IDs: EORTC-LAM-4
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MGH-CR1, NCI-V88-419A
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MGH-CR2, NCI-V88-419B
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MGH-CR3, NCI-V88-419C
|
|
7.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MGH-CR4, NCI-V88-419D
|
|
8.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MGH-CR5, NCI-V88-419E
|
|
9.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MGH-M1, NCI-V88-420A
|
|
10.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MGH-M2, NCI-V88-420B
|
|
11.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MGH-M3, NCI-V88-420C
|
|
12.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MGH-S1, NCI-V88-421A
|
|
13.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MGH-S2, NCI-V88-421B
|
|
14.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MGH-S3, NCI-V88-421C
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GBMC-M/1600/0015, UPJOHN-M/1600/0015, NCI-V95-0656
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 15 to 75
Sponsor:
Protocol IDs: WHO-MEL-TRIAL6, EU-95043
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 85 and under
Sponsor: Other
Protocol IDs: EORTC-30962, NCT00002990
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: EORTC-08971, UCLA-9902001, NCT00003279
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: NCI
Protocol IDs: JWCI-MC-4-001, CV-MMAIT-4-001, RPCI-DS-98-16, NCI-G98-1492, NCT00052156
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 90
Sponsor:
Protocol IDs: SWS-SAKK-06/98, EU-98075, NCT00003779
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: NCI
Protocol IDs: JWCI-MC-3-001A, CV-MMAIT-3-001, NCI-V99-1576, NCT00052130
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: EORTC-08971B, NCT00006352
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor:
Protocol IDs: SEG-77AML318, SEG-77AML0103
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: over 16
Sponsor: NCI
Protocol IDs: SWOG-7315/16
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor: NCI
Protocol IDs: SWOG-7416/17, MDAR-3
|
